```
=> d l12
L12 HAS NO ANSWERS
L12                STR
```



```
VAR G1=C/N
VAR G2=O/S/N
VAR G3=7/6/8
VAR G4=18/17/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   7   4  17
NUMBER OF NODES IS  24

STEREO ATTRIBUTES: NONE


=> search l12
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l11
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 13:56:03 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -     88 TO ITERATE

100.0% PROCESSED      88 ITERATIONS                          37 ANSWERS
SEARCH TIME: 00.00.01

L13           37 SEA SUB=L11 SSS FUL L12

=> d scan

L13  37 ANSWERS   REGISTRY  COPYRIGHT 2003 ACS
IN   Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[4-(2-
     hydroxyphenoxy)phenyl]- (9CI)
MF   C19 H20 N4 O3 S
```



```
t-Bu

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	107.90	365.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.88

FILE 'CAPLUS' ENTERED AT 13:56:15 ON 24 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Apr 2003 VOL 138 ISS 17
FILE LAST UPDATED: 23 Apr 2003 (20030423/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13
L14 4 L13

=> d bib abs 1-4

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2003:22837 CAPLUS
DN 138:73089
TI Preparation of N-phenyloxyphenylcarboxamides as anticholesteremic agents
IN Schmeck, Carsten; Mueller, Ulrich; Schmidt, Gunter; Pernerstorfer, Josef; Bischoff, Hilmar; Kretschmer, Axel; Voehringer, Verena; Faeste, Christiane; Haning, Helmut; Woltering, Michael
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003002519	A1	20030109	WO 2002-EP6638	20020617

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10131462 A1 20030109 DE 2001-10131462 20010629

PRAI DE 2001-10131462 A 20010629

OS MARPAT 138:73089

GI



I

AB Title compds. [I; X = O, S, SO, SO2, CH2, CHF, CF2, etc.; R1, R2 = H, alkyl; R3, R4 = H, halo, cyano, alkyl, CF3, CHF2, CH2F, vinyl, cycloalkyl; R5 = H, alkyl, halo; R6 = alkyl, Br, Cl, etc.; R7 = H, alkyl, alkanoyl; Z = NHSO2R36, NHCO2R37, NHCONR38R39, NHCOR40; R36-R40 = (substituted) alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, heteroaryl], were prepd. as anticholesteremic agents (no data). Thus, 4-(4-[tert-butyl(dimethyl)silyloxy]-3-isopropylphenoxy)-3,5-dimethylaniline (prepn. given) in THF was stirred with hexanoyl chloride and dimethylaminopyridine for 16 h at room temp. followed by further addn. of hexanoyl chloride and stirring to give 73% N-[4-(4-hydroxy-3-isopropylphenoxy)-3,5-dimethylphenyl]hexanamide.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1999:425745 CAPLUS

DN 131:87909

TI Inhibition of p38 kinase activity using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PA Bayer Corporation, USA

SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9932111	A1	19990701	WO 1998-US26080	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	AA	19990701	CA 1998-2315720	19981222
AU 9919971	A1	19990712	AU 1999-19971	19981222
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

	JP 2001526223	T2	20011218	JP 2000-525102	19981222
PRAI	US 1997-995750	A	19971222		
	WO 1998-US26080	W	19981222		

OS MARPAT 131:87909

GI



II

AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. .gtoreq.1 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compd. II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 .mu.M.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1999:425740 CAPLUS

DN 131:73648

TI Inhibition of raf kinase using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PA Bayer Corporation, USA

SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932106	A1	19990701	WO 1998-US26078	19981222
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2315717	AA	19990701	CA 1998-2315717	19981222
	AU 9921989	A1	19990712	AU 1999-21989	19981222
	EP 1047418	A1	20001102	EP 1998-965981	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526220	T2	20011218	JP 2000-525097	19981222
	BR 9814374	A	20020514	BR 1998-14374	19981222
	NO 2000003232	A	20000821	NO 2000-3232	20000621
PRAI	US 1997-996343	A	19971222		
	WO 1998-US26078	W	19981222		

OS MARPAT 131:73648

GI



II

AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. .gtoreq.1 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title compd. II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 .mu.M.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1979:6401 CAPLUS
DN 90:6401
TI Fungicidal 1,3,4-thiadiazol-2-yl ureas
IN Regel, Erik; Frohberger, Paul Ernst; Paul, Volker
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 31 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2712630	A1	19780928	DE 1977-2712630	19770323
	US 4174398	A	19791113	US 1978-882833	19780302
	NL 7803046	A	19780926	NL 1978-3046	19780321
	DK 7801325	A	19780924	DK 1978-1325	19780322
	JP 53119875	A2	19781019	JP 1978-31793	19780322
	FR 2384763	A1	19781020	FR 1978-8306	19780322
	BR 7801766	A	19781219	BR 1978-1766	19780322
	DE 2821437	A1	19781130	DE 1978-2821437	19780516
	BE 867173	A1	19780922	BE 1978-187778	19780517
	NL 7805332	A	19781121	NL 1978-5332	19780517
	FR 2390893	A1	19781215	FR 1978-15490	19780517
PRAI	DE 1977-2712630		19770323		
	GB 1977-20706		19770517		

GI



I

AB Thiadiazolylureas I (R = H, halogen; R1 = alkyl; R2 = optionally substituted phenyl) were prepd. and demonstrated fungicidal activity. Thus, 2-methylamino-1,3,4-thiadiazole was treated with 4-ClC6H4NCO to give 83.5% I (R = H, R1 = Me, R2 = 4-ClC6H4) (II). Wheat seed contaminated with 5 g Tilletia caries chlamydospores/kg was treated with 1 kg/kg II and total inhibition of germination of the chlamydospores resulted.

=> d hitstr 4

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
IT **68429-66-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 68429-66-3 CAPLUS
CN Urea, N'-[4-(4-chlorophenoxy)phenyl]-N-methyl-N-1,3,4-thiadiazol-2-yl-
(9CI) (CA INDEX NAME)



```
=> s l27
L28           3 L27

=> d bib abs hitstr 1-3

L28  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:777922  CAPLUS
DN   137:279193
TI   Preparation of imidazolylalkyl-aminopiperidines as HIV inhbitors
IN   Edlin, Christopher David; Redshaw, Sally; Smith, Ian Edward David; Walter,
     Daryl Simon
PA   F. Hoffmann-La Roche A.-G., Switz.
SO   PCT Int. Appl., 179 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.   DATE
     ---------------    ----  --------      ---------------   --------
PI   WO 2002079186      A2    20021010      WO 2002-EP3193    20020321
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003069276      A1    20030410      US 2002-104117    20020322
PRAI GB 2001-8099       A     20010330
OS   MARPAT 137:279193
GI
```



I



II

AB Title compds. I [R1 = H, alkyl, cycloalkyl, allyl, aryl, heterocyclyl; R2-3 = H, alkyl, cycloalkyl, allyl, aryl, heterocyclyl; X = S, O; A = imidazolyl] were prepd. For instance, N-tert-butoxycarbonyl-4-piperidone was used to alkylate aniline (CH2Cl2, HOAc, NaHB(OAc)3), the product converted to the corresponding carbamoyl chloride (CH2Cl2/PhMe, NaHCO3, Cl2CO) which was reacted with methylamine to give the urea intermediate. This was deprotected and the resulting piperidine alkylated with 5-methyl-2-(4-trifluoromethylphenyl)-1H-imidazole-4-carboxaldehyde (CH2Cl2, NaHB(OAc)3) to afford II. In the gp120-sCD4-CCR5 binding assay, compds. of the invention had IC50 of about 0.5 to about 1500 nM. Compds. I prevent the human immunodeficiency virus (HIV) from entering cells by blocking interaction of the viral envelope protein gp120 with a chemokine receptor on the cell surface. I are useful for the treatment of diseases mediated by the human immunodeficiency virus (HIV), either alone or in combination with other inhibitors of HIV viral replication or with pharmacoenhancers.

IT **466665-56-5P**, 1-Benzyl-3-(5-methyl-[1,3,4]thiadiazol-2-yl)-1-[1-[[5-methyl-2-(4-trifluoromethylphenyl)-1H-imidazol-4-yl]methyl]piperidin-4-yl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(HIV inhibitor; prepn. of imidazolylalkyl-aminopiperidines as HIV inhbitors)

RN 466665-56-5 CAPLUS

CN Urea, N'-(5-methyl-1,3,4-thiadiazol-2-yl)-N-[1-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]methyl]-4-piperidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L28 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 1999:425740 CAPLUS

DN 131:73648

TI Inhibition of raf kinase using substituted heterocyclic ureas

IN Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko

PA Bayer Corporation, USA

SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9932106	A1	19990701	WO 1998-US26078	19981222

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2315717	AA	19990701	CA 1998-2315717	19981222
	AU 9921989	A1	19990712	AU 1999-21989	19981222
	EP 1047418	A1	20001102	EP 1998-965981	19981222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001526220	T2	20011218	JP 2000-525097	19981222
	BR 9814374	A	20020514	BR 1998-14374	19981222
	NO 2000003232	A	20000821	NO 2000-3232	20000621
PRAI	US 1997-996343	A	19971222		
	WO 1998-US26078	W	19981222		

OS MARPAT 131:73648

GI



II

AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl contg. .gtoreq.1 5-6 membered arom. structure contg. 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temp. for 2 days gave title. compd. II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 .mu.M.

IT **229002-43-1P 229002-44-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 229002-43-1 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[6-(3-pyridinyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 229002-44-2 CAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]-N'-[6-[(6-methyl-3-pyridinyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1995:582595 CAPLUS
DN 123:33047
TI Preparation of 1-(imidazolylalkyl)-3-ureido-1,4-benzodiazepine derivatives as cholecystokinin (CCK) antagonists
IN Sato, Yoshiya
PA Fujisawa Pharmaceuticals Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07002843	A2	19950106	JP 1994-45559	19940316
PRAI	GB 1993-8013		19930419		
	GB 1993-22270		19931029		

OS MARPAT 123:33047
GI



I



II



AB The title compds. (I; R1 = H, halo; R2 = H, imino-protective group; R3 = Ph, heterocyclyl, or phenyl-lower alkyl each optionally substituted by .gtoreq.1 substituents; A = lower alkylene), useful for treating disorders of appetite regulation (e.g. loss of appetite), diseases related to exacerbated function of the smooth muscle of intestinal tract, anxiety, and mental diseases (e.g. schizophrenia), are prepd. Thus, 4-chlorophenyl

isocyanate was added to a soln. of 1,4-benzodiazepine deriv. (II; R = trityl, R1 = H) in THF at room temp. and the resulting mixt. was stirred for 2 h to give, after detritylation by treatment with 6 N aq. HCl/MeOH, a title compd. II.HCl (R = H, R1 = Q) (III). III in vitro inhibited 67.0% the binding of [125I]CCK-8 to a CCk receptor prepn. from homogenized rat cerebral cortex.

IT **163486-65-5P 163486-70-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (imidazolylalkyl)ureidobenzodiazepinone derivs. as cholecystokinin (CCK) antagonists)

RN 163486-65-5 CAPLUS
CN Urea, N-[5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-1H-1,4-benzodiazepin-3-yl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)



RN 163486-70-2 CAPLUS
CN Urea, N-[5-(2-fluorophenyl)-2,3-dihydro-1-(1H-imidazol-4-ylmethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(5-methyl-1,3,4-thiadiazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl